Sign in
TerminatedNo phase

Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)

Key facts

Who runs it
Hi-Q Marine Biotech International, Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
87 people enrolled
Started
1 Oct 2019
Ended
31 Jul 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Oligo Fucoidan
  • Placebo
Record updated
13 January 2025
Why it stopped
After interim analysis, we planned to recruit 100 participants. However, due to COVID-19 challenges, statistician advised each group needs at least 30 samples (Gay, 1992). The sponsor and team decided to terminate the trial early for valid data.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Age > 18 years
  • ECOG PS 0-2
  • Histologically or cytologically documented unresectable HCC
  • Measurable disease by RECIST criteria
  • HCC without well control
  • Child-Pugh A-B
  • Albumin ≥ 2.8 g/dl
  • Serum total bilirubin ≤ 3 mg/dl
  • INR ≤ 2.3 or PT ≤ 6 seconds above control
  • WBC ≥ 2,500/µl
  • ANC ≥ 1,000/µl
  • Platelets ≥ 50,000/µl
  • Hb ≥ 8.5 g/dl
  • Creatinine ≤ 1.5 x ULN; AND

Who cannot take part

  • Prior or concomitant systemic anti-cancer treatment for HCC, including:
  • Systemic chemotherapy (TACE is allowed)
  • Unable to take oral medications
  • BMT or stem cell rescue < 4 months; organ transplant
  • Major surgical procedure, open biopsy, or significant traumatic injury < 4 weeks or those who receive minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 2 weeks
  • Patients taking narrow therapeutic index medications will be monitored closely. These include warfarin, phenytoin, quinidine, carbamazepine, phenobarbital, cyclosporine, and digoxin
  • Investigational anti-cancer agents
  • Severe and/or uncontrolled medical conditions:
  • History of poor compliance with anti-hypertensive agents
  • Active or uncontrolled infection
  • Unstable angina
  • GI bleeding < 30 days
  • Severe renal impairment which requires dialysis; proteinuria > grade 2
  • HIV infection
  • Metastatic tumors
  • Uncontrolled high blood pressure
  • CHF
  • MI or CVA < 6 months

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A randomized, double-blind, controlled trial was conducted evaluating the efficacy of Oligo-Fucoidan with the molecular weight ranged from 500 to 800 Da. as a supplemental therapy in patients with advanced hepatocellular carcinoma. The previous study results demonstrate the advantages of Oligo-Fucoidan in improving the disease control rate in metastatic colorectal cancer. The previous study might provide insights into the development of cancer treatments, particularly in the combination of natural or herbal products with chemotarget agents.

The 2 groups in the trial

  • Treatment & Oligo FucoidanTreatment being tested

    4.4 g Oligo Fucoidan powder by six months, BID

    Treatment: Oligo Fucoidan

  • Treatment & PlaceboPlacebo, for comparison

    4.4 g Placebo powder by six months, BID

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
13 January 2025